Epigenetic control of skeletal development by the histone methyltransferase Ezh2

Amel Dudakovic, Emily T. Camilleri, Fuhua Xu, Scott M. Riester, Meghan Elizabeth McGee Lawrence, Elizabeth W. Bradley, Christopher R. Paradise, Eric A. Lewallen, Roman Thaler, David R. Deyle, A. Noelle Larson, David G. Lewallen, Allan B. Dietz, Gary S. Stein, Martin A. Montecino, Jennifer J. Westendorf, Andre J. Van Wijnen

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Epigenetic control of gene expression is critical for normal fetal development. However, chromatin-related mechanisms that activate bone-specific programs during osteogenesis have remained underexplored. Therefore, we investigated the expression profiles of a large cohort of epigenetic regulators (>300) during osteogenic differentiation of human mesenchymal cells derived from the stromal vascular fraction of adipose tissue (AMSCs). Molecular analyses establish that the polycomb group protein EZH2 (enhancer of zeste homolog 2) is down-regulated during osteoblastic differentiation of AMSCs. Chemical inhibitor and siRNA knockdown studies show that EZH2, a histone methyltransferase that catalyzes trimethylation of histone 3 lysine 27 (H3K27me3), suppresses osteogenic differentiation. Blocking EZH2 activity promotes osteoblast differentiation and suppresses adipogenic differentiation of AMSCs. High throughput RNA sequence (mRNASeq) analysis reveals that EZH2 inhibition stimulates cell cycle inhibitory proteins and enhances the production of extracellular matrix proteins. Conditional genetic loss of Ezh2 in uncommitted mesenchymal cells (Prrx1-Cre) resultsinmultiple defectsinskeletal patterning and bone formation, including shortened forelimbs, craniosynostosis, and clinodactyly. Histological analysis and mRNASeq profiling suggest that these effects are attributable to growth plate abnormalities and premature cranial suture closure because of precocious maturation of osteoblasts. We conclude that the epigenetic activity of EZH2 is required for skeletal patterning and development, but EZH2 expression declines during terminal osteoblast differentiation and matrix production.

Original languageEnglish (US)
Pages (from-to)27604-27617
Number of pages14
JournalJournal of Biological Chemistry
Volume290
Issue number46
DOIs
StatePublished - Nov 13 2015

Fingerprint

Osteoblasts
Epigenomics
Bone
Polycomb-Group Proteins
Extracellular Matrix Proteins
Osteogenesis
Gene expression
Histones
Small Interfering RNA
Lysine
Chromatin
Cranial Sutures
Cells
Throughput
RNA
Tissue
RNA Sequence Analysis
Craniosynostoses
Cell Cycle Proteins
Growth Plate

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Dudakovic, A., Camilleri, E. T., Xu, F., Riester, S. M., McGee Lawrence, M. E., Bradley, E. W., ... Van Wijnen, A. J. (2015). Epigenetic control of skeletal development by the histone methyltransferase Ezh2. Journal of Biological Chemistry, 290(46), 27604-27617. https://doi.org/10.1074/jbc.M115.672345

Epigenetic control of skeletal development by the histone methyltransferase Ezh2. / Dudakovic, Amel; Camilleri, Emily T.; Xu, Fuhua; Riester, Scott M.; McGee Lawrence, Meghan Elizabeth; Bradley, Elizabeth W.; Paradise, Christopher R.; Lewallen, Eric A.; Thaler, Roman; Deyle, David R.; Larson, A. Noelle; Lewallen, David G.; Dietz, Allan B.; Stein, Gary S.; Montecino, Martin A.; Westendorf, Jennifer J.; Van Wijnen, Andre J.

In: Journal of Biological Chemistry, Vol. 290, No. 46, 13.11.2015, p. 27604-27617.

Research output: Contribution to journalArticle

Dudakovic, A, Camilleri, ET, Xu, F, Riester, SM, McGee Lawrence, ME, Bradley, EW, Paradise, CR, Lewallen, EA, Thaler, R, Deyle, DR, Larson, AN, Lewallen, DG, Dietz, AB, Stein, GS, Montecino, MA, Westendorf, JJ & Van Wijnen, AJ 2015, 'Epigenetic control of skeletal development by the histone methyltransferase Ezh2', Journal of Biological Chemistry, vol. 290, no. 46, pp. 27604-27617. https://doi.org/10.1074/jbc.M115.672345
Dudakovic, Amel ; Camilleri, Emily T. ; Xu, Fuhua ; Riester, Scott M. ; McGee Lawrence, Meghan Elizabeth ; Bradley, Elizabeth W. ; Paradise, Christopher R. ; Lewallen, Eric A. ; Thaler, Roman ; Deyle, David R. ; Larson, A. Noelle ; Lewallen, David G. ; Dietz, Allan B. ; Stein, Gary S. ; Montecino, Martin A. ; Westendorf, Jennifer J. ; Van Wijnen, Andre J. / Epigenetic control of skeletal development by the histone methyltransferase Ezh2. In: Journal of Biological Chemistry. 2015 ; Vol. 290, No. 46. pp. 27604-27617.
@article{a9a8b0a8367b43e2b8ede9bee8f611f7,
title = "Epigenetic control of skeletal development by the histone methyltransferase Ezh2",
abstract = "Epigenetic control of gene expression is critical for normal fetal development. However, chromatin-related mechanisms that activate bone-specific programs during osteogenesis have remained underexplored. Therefore, we investigated the expression profiles of a large cohort of epigenetic regulators (>300) during osteogenic differentiation of human mesenchymal cells derived from the stromal vascular fraction of adipose tissue (AMSCs). Molecular analyses establish that the polycomb group protein EZH2 (enhancer of zeste homolog 2) is down-regulated during osteoblastic differentiation of AMSCs. Chemical inhibitor and siRNA knockdown studies show that EZH2, a histone methyltransferase that catalyzes trimethylation of histone 3 lysine 27 (H3K27me3), suppresses osteogenic differentiation. Blocking EZH2 activity promotes osteoblast differentiation and suppresses adipogenic differentiation of AMSCs. High throughput RNA sequence (mRNASeq) analysis reveals that EZH2 inhibition stimulates cell cycle inhibitory proteins and enhances the production of extracellular matrix proteins. Conditional genetic loss of Ezh2 in uncommitted mesenchymal cells (Prrx1-Cre) resultsinmultiple defectsinskeletal patterning and bone formation, including shortened forelimbs, craniosynostosis, and clinodactyly. Histological analysis and mRNASeq profiling suggest that these effects are attributable to growth plate abnormalities and premature cranial suture closure because of precocious maturation of osteoblasts. We conclude that the epigenetic activity of EZH2 is required for skeletal patterning and development, but EZH2 expression declines during terminal osteoblast differentiation and matrix production.",
author = "Amel Dudakovic and Camilleri, {Emily T.} and Fuhua Xu and Riester, {Scott M.} and {McGee Lawrence}, {Meghan Elizabeth} and Bradley, {Elizabeth W.} and Paradise, {Christopher R.} and Lewallen, {Eric A.} and Roman Thaler and Deyle, {David R.} and Larson, {A. Noelle} and Lewallen, {David G.} and Dietz, {Allan B.} and Stein, {Gary S.} and Montecino, {Martin A.} and Westendorf, {Jennifer J.} and {Van Wijnen}, {Andre J.}",
year = "2015",
month = "11",
day = "13",
doi = "10.1074/jbc.M115.672345",
language = "English (US)",
volume = "290",
pages = "27604--27617",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "46",

}

TY - JOUR

T1 - Epigenetic control of skeletal development by the histone methyltransferase Ezh2

AU - Dudakovic, Amel

AU - Camilleri, Emily T.

AU - Xu, Fuhua

AU - Riester, Scott M.

AU - McGee Lawrence, Meghan Elizabeth

AU - Bradley, Elizabeth W.

AU - Paradise, Christopher R.

AU - Lewallen, Eric A.

AU - Thaler, Roman

AU - Deyle, David R.

AU - Larson, A. Noelle

AU - Lewallen, David G.

AU - Dietz, Allan B.

AU - Stein, Gary S.

AU - Montecino, Martin A.

AU - Westendorf, Jennifer J.

AU - Van Wijnen, Andre J.

PY - 2015/11/13

Y1 - 2015/11/13

N2 - Epigenetic control of gene expression is critical for normal fetal development. However, chromatin-related mechanisms that activate bone-specific programs during osteogenesis have remained underexplored. Therefore, we investigated the expression profiles of a large cohort of epigenetic regulators (>300) during osteogenic differentiation of human mesenchymal cells derived from the stromal vascular fraction of adipose tissue (AMSCs). Molecular analyses establish that the polycomb group protein EZH2 (enhancer of zeste homolog 2) is down-regulated during osteoblastic differentiation of AMSCs. Chemical inhibitor and siRNA knockdown studies show that EZH2, a histone methyltransferase that catalyzes trimethylation of histone 3 lysine 27 (H3K27me3), suppresses osteogenic differentiation. Blocking EZH2 activity promotes osteoblast differentiation and suppresses adipogenic differentiation of AMSCs. High throughput RNA sequence (mRNASeq) analysis reveals that EZH2 inhibition stimulates cell cycle inhibitory proteins and enhances the production of extracellular matrix proteins. Conditional genetic loss of Ezh2 in uncommitted mesenchymal cells (Prrx1-Cre) resultsinmultiple defectsinskeletal patterning and bone formation, including shortened forelimbs, craniosynostosis, and clinodactyly. Histological analysis and mRNASeq profiling suggest that these effects are attributable to growth plate abnormalities and premature cranial suture closure because of precocious maturation of osteoblasts. We conclude that the epigenetic activity of EZH2 is required for skeletal patterning and development, but EZH2 expression declines during terminal osteoblast differentiation and matrix production.

AB - Epigenetic control of gene expression is critical for normal fetal development. However, chromatin-related mechanisms that activate bone-specific programs during osteogenesis have remained underexplored. Therefore, we investigated the expression profiles of a large cohort of epigenetic regulators (>300) during osteogenic differentiation of human mesenchymal cells derived from the stromal vascular fraction of adipose tissue (AMSCs). Molecular analyses establish that the polycomb group protein EZH2 (enhancer of zeste homolog 2) is down-regulated during osteoblastic differentiation of AMSCs. Chemical inhibitor and siRNA knockdown studies show that EZH2, a histone methyltransferase that catalyzes trimethylation of histone 3 lysine 27 (H3K27me3), suppresses osteogenic differentiation. Blocking EZH2 activity promotes osteoblast differentiation and suppresses adipogenic differentiation of AMSCs. High throughput RNA sequence (mRNASeq) analysis reveals that EZH2 inhibition stimulates cell cycle inhibitory proteins and enhances the production of extracellular matrix proteins. Conditional genetic loss of Ezh2 in uncommitted mesenchymal cells (Prrx1-Cre) resultsinmultiple defectsinskeletal patterning and bone formation, including shortened forelimbs, craniosynostosis, and clinodactyly. Histological analysis and mRNASeq profiling suggest that these effects are attributable to growth plate abnormalities and premature cranial suture closure because of precocious maturation of osteoblasts. We conclude that the epigenetic activity of EZH2 is required for skeletal patterning and development, but EZH2 expression declines during terminal osteoblast differentiation and matrix production.

UR - http://www.scopus.com/inward/record.url?scp=84946925427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946925427&partnerID=8YFLogxK

U2 - 10.1074/jbc.M115.672345

DO - 10.1074/jbc.M115.672345

M3 - Article

VL - 290

SP - 27604

EP - 27617

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 46

ER -